TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer

Table 4

Univariate analysis of factors related to mPFS and mOS of patients in this study (N=80).

Characteristics	mPFS (months)	value	mOS (months)	value
Age (years)
≥45	5.50		10.2
<45	6.80	0.613	13.4	0.395
Pathological type
Squamous cell	6.10		11.3
Adenocarcinoma	3.90	0.639	7.60	0.791
ECOG PS
0	7.30		13.4
1	5.90	0.562	11.2	0.823
Size of primary tumor (cm)
≥5	6.70		13.2
<5	6.10	0.115	11.2	0.895
First-line chemotherapy with bevacizumab
Yes	6.30		11.3
No	4.45	0.400	8.00	0.157
Location of metastatic tumors
Lung	8.30		15.3
Others	6.10	0.931	11.3	0.130